Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 261

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 261
---
 a straight-line basis over the lease term in the income statement.The following table summarizes information related to the Company’s leases (in thousands):March 31, 2025December 31, 2024Assets:Operating lease right-of-use assets$— $787 Liabilities:Operating lease liabilities, current$— $268 Operating lease liabilities, non-current— 565 Total operating lease liabilities$— $833 

15

Rent expense for the three months ended March 31, 2025 and 2024 is presented on the following table (in thousands):Three Months Ended March 31,20252024Operating lease rent expense$74 $115 Cash paid for leases and included in operating cash flows for the three months ended March 31, 2025 and 2024 is presented on the following table (in thousands):Three Months Ended March 31,20252024Cash paid included in operating cash flows$99 $126 

7. License Agreements

Former Bristol-Myers Squibb Company License AgreementOn April 9, 2014, the Company entered into a license agreement (as amended the “BMS License Agreement”) with BMS for exclusive rights for certain patents and a non-exclusive license for certain technology and know-how pertaining to FYARRO. The BMS License Agreement will remain in effect from the effective date of April 9, 2014 until expiration of all milestone and royalty payment obligations under the agreement, unless terminated by either of the parties pursuant to the terms of the BMS License Agreement, including providing advance notice as specified in the agreement. Under the terms of the BMS License Agreement, BMS agreed to supply the Company with licensed products of FYARRO necessary for clinical or non-clinical development. Under the terms of the BMS License Agreement, BMS is entitled to receive royalties on net sales from licensed products under the agreement and any sublicense fees. During the three months ended March 31, 2025 and 2024, royalties on net product sales were $0.5 million and $0.4 million, respectfully. No payments related to sublicense fees were paid during the three months ended March 31, 2025 or 2024. On August 30, 2021, the Company and BMS entered into Amendment No. 1 (the “Amendment”) to the BMS License Agreement related to certain intellectual property rights of BMS pertaining to the compound known as FYARRO. Under the